We are international
Donate
TEXT SIZE   
back

Myeloma Minute
July 26, 2012
07.26.12
July 26, 2012
Share the Minute Facebook Tweet! Clinical Trials Donate to the IMF


Food and Drug Administration approval of Onyx’s Kyprolis™ (carfilzomib) offers hope to myeloma patients who have run out of options when available therapies have stopped working.

 

FDA Approval of Kyprolis Gives Patients a Critical New Option

Kyprolis was approved by the FDA on Friday July 20th for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent (thalidomide or lenalidomide) and have demonstrated disease progression on or within sixty days of the completion of the last therapy.

“This is important news for patients, because Kyprolis provides a new option for patients to achieve remission and extend survival,” says Brian G.M. Durie, M.D., Chairman and Co-founder of the IMF. “Congratulations to the Onyx team.”

The IMF appreciated the opportunity to participate at the recent ODAC hearing. IMF Vice President Diane Moran and IMF Director of Support Groups Robin Tuohy, along with her husband Michael who is a myeloma patient, presented dramatic and powerful testimony demonstrating the dire need to approve new drugs such as Kyprolis.

“The committee saw first-hand what access to a new drug like Kyprolis means for patients like Michael Tuohy, who can now look forward to more years with his family, watch his children graduate from college and even start families of their own,” says Susie Novis, President and Co-founder of the IMF. She continued, “An important area of focus for the IMF is how to best support myeloma patients and their families with information, education and unparalleled expertise. The research division of the IMF, the International Myeloma Working Group, adds expertise by providing guidance as to the best uses of new drugs such as Kyprolis. Kyprolis is a powerful new addition to our ‘toolkit.’ We are just beginning to understand the full potential of this novel therapy, and as always the IMF is here to help. Kyprolis will be commercially available August 1st and the IMF, through the hotline, the Myeloma Post, the website, publications, and seminars, is ready to answer all questions.” A Kyprolis tip card and an “Understanding Kyprolis” brochure (coming soon) are available both in hard copy and on the IMF website.

READ MORE | Visit the Kyprolis Resource Page | Kyprolis Tip Card


Read About the Kyprolis Study That Led to FDA Approval


Kyprolis was approved by the FDA based on results from a recent clinical trial. Read about the results of that study, published in the latest issue of the medical journal Blood.
READ MORE




Our Support Group Leaders Weigh In



“I was doubly pleased to see the FDA approve Kyprolis last Friday. First of all, it adds another important treatment option in the arsenal of weapons to manage our myeloma with good quality of life. Second, living in the San Francisco Bay Area, I’ve gotten to personally know many of the folks at Proteolix, who developed Kyprolis, and then Onyx, who acquired them. They are focused on extending the lives of myeloma patients and realize the importance of not only creating a successful new drug but also providing a valuable patient assistance program to accompany it called Onyx 360.”

Jack Aiello
Diagnosed 1995
Co-facilitator of the SF Bay Area MM Support Group

“I am thrilled to know there is another treatment choice available for the MM community! Our Philadelphia support group has numerous members with advanced myeloma and Kyprolis offers them another avenue for hope. Although MM is still considered to be incurable, Kyprolis helps us to have increased confidence that this illness can really be seen as a chronic disease.”

Maddie Hunter
Co-Leader of the Philadelphia Multiple Myeloma Networking Group

“One day after Onyx announced the FDA approval of Kyprolis (carfilzomib) for myeloma patients whose disease is progressing after two prior therapies, we had our Southeastern Virginia Multiple Myeloma Support Group meeting. Members were very excited about the approval, particularly those who meet the criteria for the new drug and were concerned about limited options for new therapies.

“They were also impressed by the rapid standup of the Onyx patient assistance service. When they called the number for Onyx Pharmaceuticals 360 (1-855-ONYX-360), a comprehensive patient and caregiver support and services program designed to help patients navigate the treatment journey, they learned about its services. These include info and assistance on reimbursement and payment support, treatment support and other support. They spoke to a dedicated Oncology Nurse Advocate who is available to assist patients, caregivers and healthcare providers regarding Kyprolis.

“One of our members shared the results of her call to them: ‘I just got off the phone with one of the nurses for Onyx…she was very helpful. She said carfilzomib is covered by Medicare Part B….she suggested that I go to their website and fill out a form which needs to be signed by the physician. This form will give Onyx the patient's authorization to contact the insurance companies involved to see what their particular insurance company will cover. In our case, it will be Medicare Part B & his supplemental policy. After the doctor signs the form, it can then be faxed, or mailed back to Onyx.’

“Bottom line - great news for myeloma patients. Thanks to all involved, including the Onyx Team, the IMF, IMF's Robin and Michael Tuohy for their testimony before the FDA committee, all the patients who participated in clinical trials, everyone else and all other organizations who helped add this weapon to the Beat Myeloma arsenal.”

Jerry Walton
Southeastern Virginia Multiple Myeloma Support Group (“SEVA”)
 

Watch the ODAC Hearing Webcast



Follow the links below to watch IMF Vice President Diane Moran, IMF Director of Support Groups Robin Tuohy, and Robin’s husband and myeloma patient Michael Tuohy provide their moving testimony in support of Kyprolis approval.

They provide their testimonies in Part 3 of the webcast. The full ODAC committee hearing, where an expert panel ultimately voted 11-0 to recommend that the FDA approve Kyprolis, can be viewed at the links below. This hearing was held on June 20, 2012.



Part 1 | Part 2 | Part 3

To view this webcast, you can make sure your computer has the necessary Adobe Connect plug-ins at this website.

 

 
Join Our Mailing List  
 
12650 Riverside Drive, Suite 206 | North Hollywood, CA 91607-3421
Privacy Policy | Unsubscribe 
www.myeloma.org
=
 related videos
 related articles
#AskDrDurie: My Mai...
#AskDrDurie: Can Mye...
10 PASSI PER CURA MI...
10 Steps to Better C...
10 Steps to Happy Ho...
2011 IMF Holiday Gif...
New Study: The Searc...
Comprender El Tratam...
...
ABOUT BSRI™
ABOUT BSRI®
Advocacy Update - Ap...
Advocacy Update - Ma...
Advocacy Update - Oc...
Advocacy Update - Se...
Advocacy Update: The...
As the Bill Turns......
ASCO 2012: Dr. Pasho...
ASCO 2013: Dr. Jakub...
ASCO 2013: Dr. Lonia...
ASCO 2013: Dr. Pande...
ASCO 2013: Dr. Usman...
ASCO 2013: Dr. Weise...
ASH 2012: A PREVIEW
ASH 2013: Dr. Ken An...
Audio Recording of C...
August 2013 Advocate...
Breaking News: Pomal...
FDA Recognition of E...
Freelite and Hevylit...
Health Reform and Yo...
Highlights from the ...
IMF 6th Annual Comed...
IMF Board Member Edi...
IMF Nurse Leadership...
IMF Responds to Prop...
IMWG 2014 Conference...
It is Officially Mye...
jc test
Live from ASH 2012: ...
Live! The Boca Raton...
Living Well with Mye...
Living Well With Mye...
Myelom Merkur - Früh...
MYELOMA AWARENESS MO...
Myeloma Canada Annou...
Myeloma Minute Apri...
Myeloma Minute Apri...
Myeloma Minute Apri...
Myeloma Minute Febr...
Myeloma Minute Janu...
Myeloma Minute June...
Myeloma Minute Marc...
Myeloma Minute May ...
Myeloma Minute Nove...
Myeloma Minute Octo...
Myeloma Minute Octo...
Myeloma MinuteJune 1...
Myeloma MinuteMay 24...
Myeloma Today Spring...
New! Free Teleconfer...
Patienten Handbuch
Pomalidomide + carfi...
Should Myeloma Patie...
Special Myeloma Minu...
STEP 7: CONSOLIDATIO...
STEP 8: KEEPING TRAC...
Stillwater, Minn., M...
Teleconference: Myel...
The Emerging Role of...
The Hope Society
THE IMF AT ASH 2012
The IMF Gains Nation...
The IMF Spearheads N...
The Importance of Cl...
The IMWG Conference ...
The International My...
The International My...
The International My...
View the IMF’s Multi...
Webcast from the 201...
Клиническое значение...

ASCO 2012: Dr. Pashos - Race- and health-related quality of life among patients newly diagnosed with multiple myeloma
ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.
ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.
ASCO 2013: Dr. Pandey - Beneficial effect of complete response and type of therapy in multiple myeloma.
ASCO 2013: Dr. Usmani - Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Weisel - MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).
jc test
#AskDrDurie: My Maintenance was Stopped Because the Side Effects were Too Bad. How Common is That?
#AskDrDurie: Can Myeloma Run In The Family?
10 PASSI PER CURA MIGLIORE®
10 Steps to Better Care®
10 Steps to Stress Control – From Fear to Hope
10 Steps to Happy Holidays
2011 IMF Holiday Gift Boutique

New Study: The Search for Criteria to Diagnose Active Myeloma at an Early Stage

Comprender El Tratamiento con Dosis Altas con Rescate de Células Madre



Third in the popular series of debates that debuted in Amsterdam in 2012.

Conference aired at 1:00 pm CEST/7:00 am Eastern/4:00 am Pacific

ABOUT BSRI™
ABOUT BSRI®
Advocacy Update - April 2013
Advocacy Update - March 2013
Advocacy Update - October 2013
Advocacy Update - September 2012
Advocacy Update: The Healthcare Landscape in the Aftermath of the 2012 Elections
As the Bill Turns...Episode 3
ASCO 2012: Dr. Pashos - Race- and health-related quality of life among patients newly diagnosed with multiple myeloma
ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.
ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.
ASCO 2013: Dr. Pandey - Beneficial effect of complete response and type of therapy in multiple myeloma.
ASCO 2013: Dr. Usmani - Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Weisel - MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).
ASH 2012: A PREVIEW
ASH 2013: Dr. Ken Anderson's Overview
Audio Recording of Consensus on Care: Management of Side Effects of Novel Therapies Teleconference
August 2013 Advocate of the Month: Judy Lewis
Breaking News: Pomalyst® (pomalidomide) Approved by the FDA for Relapsed Myeloma
FDA Recognition of Extended Survival with VELCADE® Indicates Important New Progress in Treating the Disease
Freelite and Hevylite will help the Black Swan Research Initiative find the best treatment to cure multiple myeloma
Health Reform and You: The ABC’s of the ACA for Private Health Insurance
Highlights from the 5th Annual IMWG Summit: Part 2
IMF 6th Annual Comedy Celebration
benefiting the Peter Boyle Research Fund
October 27, 2012
IMF Board Member Edith Mitchell, M.D., FACP, Named 2012 Recipient Of ASCO Humanitarian Award
IMF Nurse Leadership Board (NLB) White Paper on Subcutaneous Velcade® (bortezomib)
IMF Responds to Proposed Changes in CMS PET Scan Policy
IMWG 2014 Conference Series Debate: Making Sense of Treatment
It is Officially Myeloma Awareness Month Across the Country!
jc test
Live from ASH 2012: Journalists’ Workshop with Leading Myeloma Experts
Live! The Boca Raton Patient & Family Seminar
Living Well with Myeloma Teleconference Series:
How to Prevent Infection in Myeloma Patients
Living Well With Myeloma:
Understanding the Immune System and Lab Values in Myeloma
Myelom Merkur - Frühjahr 2012 - #901
MYELOMA AWARENESS MONTH 2012 FACT-A-DAY
Myeloma Canada Announces Recipient of this Year’s Research Grant
Myeloma Minute
April 11, 2013
Myeloma Minute
April 18, 2013
Myeloma Minute
April 26, 2012
Myeloma Minute
February 7, 2013
Myeloma Minute
January 31, 2013
Myeloma Minute
June 28, 2012
Myeloma Minute
March 7, 2013
Myeloma Minute
May 17, 2012
Myeloma Minute
November 8, 2012
Myeloma Minute
October 24, 2013
Myeloma Minute
October 25, 2012
Myeloma Minute
June 13, 2013
Myeloma Minute
May 24, 2012
Myeloma Today Spring 2013
New! Free Teleconference: Myeloma Updates 2012
Post ASCO/EHA/IMWG Summit
Patienten Handbuch
Pomalidomide + carfilzomib trial recruiting patients.
Should Myeloma Patients Get a Flu Shot? If So, Which One?
Special Myeloma Minute on FDA Approved Data for VELCADE®, including long-term survival data
STEP 7: CONSOLIDATION AND MAINTENANCE - ARE THEY NEEDED? REFERENCES
STEP 8: KEEPING TRACK OF THE MYELOMA - MONITORING WITHOUT MYSTERY
Stillwater, Minn., Myeloma Support Group Marks "Centennial" Anniversary
Teleconference: Myeloma Updates 2012
Post ASCO/EHA/IMWG Summit
The Emerging Role of Kyprolis in the Treatment Paradigm
The Hope Society
THE IMF AT ASH 2012
The IMF Gains National Recognition for Myeloma Awareness Month in 2014
The IMF Spearheads New Coalition’s First Meeting on State Health Exchanges
The Importance of Clinical Trial Participation - A teleconference with Dr. Brian G. M. Durie
September 8,2011
The IMWG Conference Series "Making Sense of Treatment"
June 11, 2014
The International Myeloma Foundation announces partnership with Onyx Pharmaceuticals to support Black Swan Research Initiative®
The International Myeloma Foundation Reports Live from the 2013 ASH Meeting in New Orleans
The International Myeloma Foundation to Convene First Global Leaders Summit in Stockholm to Raise Disease Awareness and Increase Access to Life-Saving Treatments
View the IMF’s Multiple Myeloma Journalists’ Workshop and Webcast from ASH 2013 in New Orleans
Webcast from the 2014 Boca Raton Patient & Family Seminar
February 28 - March 1, 2014

Клиническое значение электрофореза белковых фракций